AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

Clario and PathAI Join Forces to Streamline GI Clinical Trials with Integrated Solutions

NextEdge Admin

14 Oct 2024

2 min 10 sec

Clario has formed a strategic partnership with PathAI, an AI-powered digital pathology provider, to streamline gastrointestinal (GI) clinical trials. This collaboration aims to create a comprehensive solution that integrates anatomical pathology services with advanced video endoscopy assessments, offering a single-vendor experience for contract research organizations (CROs) and sponsors.

The initiative will encompass a full end-to-end process, including training, logistics, tissue processing, slide digitization, image analysis, and data transfer, all managed under expert medical and scientific oversight. This partnership is set to simplify workflows at clinical trial sites, enhancing training, reporting, and document management.

Marcela Vieira, Clario's gastroenterology medical director, expressed excitement about the collaboration, highlighting that it combines their expertise in GI trials—backed by over 130 studies using advanced imaging technologies—with PathAI’s innovative capabilities in patient care and research. The integration of endoscopy and histopathology is expected to open new avenues for clinical research.

PathAI will contribute its network of expert GI pathologists and focus on improving the handling of specimens and histological assessments. Their AI-driven solutions are designed to enhance evaluations for ulcerative colitis (UC), minimize variability in histological scoring, and expedite biomarker discovery.

Matt Grow, chief business officer of PathAI Biopharma, noted that this partnership will provide a state-of-the-art approach to assessing therapeutic efficacy in inflammatory bowel disease (IBD) clinical trials, ultimately accelerating therapy development.